Fecha de la publicación: 11/08/2021
Autor: Ferrán Plá Sánchez (1), Guillermo Moñux Ducajú (2), Oscar Uclés Cabeza (3), Rodrigo Rial (2), Adriana Baturone Blanco (3), Julio Reina Barrera (3), Antonio Martín Conejero (3), Francisco Javier Serrano Hernando (3)
1Servicio de Angiología y Cirugía Vascular, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, España. Electronic address: firstname.lastname@example.org.
2Servicio de Angiología y Cirugía Vascular, Hospital Universitario HM Torrelodones, Madrid, España.
3Servicio de Angiología y Cirugía Vascular, Hospital Clínico San Carlos, Madrid, España.
Objective: To analyze the results of endovascular treatment of venous anastomotic stenosis (VAS) in humero-axillary arteriovenous grafts (HAG), comparing outcomes between patent and thrombosed HAG.
Material and methods: A retrospective cohort study was made of endovascular treated patients because of a VAS in a HAG between January 2009 and December 2019. Group A: Thrombosed HAG secondary to a VAS. Group B: Patent HAG with a VAS detected during follow-up. Technical success was defined as residual stenosis after treatment <30%, and clinical success as satisfactory immediate dialysis after surgery. After ET a biannual clinical and ultrasound follow-up was performed.
Statistical analysis: Survival analysis was performed for time-to-event data to assess patency.
Results: Group A: 55 patients. Group B: 22. There were no significative differences in demographic and anatomical factors between groups. Technical and clinical success were 100% in Group B and 94.5% and 91% respectively in Group A. Primary patency at 1, 6 and 12 months was: Group A: 81.8%, 22.4% and 15.7% respectively. Group B: 100%, 85.9%, 76.4% (p<0.001). Secondary patency at 1, 6 and 12 months was: Group A: 85.2%, 45.8% and 31.3% respectively. Group B 100%, 95.3%, 95.2% (p<0.001). Use of non-covered stents was associated with an increased risk of occlusion (HR 2.669 95% CI 1.146-6.216, p=0.010).
Conclusion: A higher patency of EV performed on a patent HAG is expected. It is therefore advisable to develop surveillance programs that are capable to detect VAS before its occlusion.
Copyright © 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.